Kitzmiller Andrew S.'s Form 4 filing
Meridian Bioscience Inc · filed Feb 28, 2022
- Accession no.
- 0001127602-22-006985
- Filed
- Feb 28, 2022
- Trade date
- Feb 25, 2022
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $100.2K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kitzmiller Andrew S.CIK 0001795272 | Officer (EVP & CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 25, 2022 | Common Stock | PPurchaseAcquired | +4,028 | $24.87F1 | +$100,176.36 | 11,528 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported price is a weighted average price. These shares were purchased in multiple transactions ranging from $24.8251 to $24.8698. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
Referenced by the price of 1 transaction in Table I.